Literature DB >> 17361007

Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study.

Oliver W J Quarrell, Alan S Rigby, L Barron, Y Crow, A Dalton, N Dennis, A E Fryer, F Heydon, E Kinning, A Lashwood, M Losekoot, L Margerison, S McDonnell, P J Morrison, A Norman, M Peterson, F L Raymond, S Simpson, E Thompson, J Warner.   

Abstract

OBJECTIVE: To obtain penetrance data for Huntington's disease when DNA results are in the range of 36-39 CAG repeats and assess the consistency of reporting the upper allele from two reference centres.
METHOD: Data were collected anonymously on age of onset or age last known to be unaffected from a cohort of individuals with results in this range. DNA samples were re-analysed in two reference centres. Kaplan-Meier analysis was used to construct an age of onset curve and penetrance figures.
RESULTS: Clinical data and concordant DNA results from both reference centres were available for 176 samples; penetrance figures (and 95% confidence intervals) for this cohort, at age 65 and 75 years, were 63.9% (55.5% to 73.2%) and 74.2% (64.2% to 84.2%), respectively. Inclusion of 28 additional subjects for whom repeat DNA results were unavailable, obtained from only one reference centre, or discrepant by one repeat within this range, gave penetrance data (including 95% confidence intervals) at ages 65 and 75 years of 62.4% (54.4% to 70.4%) and 72.7.% (63.3% to 82.1%), respectively. 238 duplicate results were available from the reference centres; 10 (4.2%) differed by one CAG repeat in the reporting of the upper allele and in two (0.84%) of these cases the discrepancy was between 39 and 40 repeats.
CONCLUSION: When DNA results are in this range, a conservative approach is to say that there is at least a 40% chance the person will be asymptomatic at age 65 years and at least a 30% chance the person will be asymptomatic at age 75 years.

Entities:  

Mesh:

Year:  2007        PMID: 17361007      PMCID: PMC2598018          DOI: 10.1136/jmg.2006.045120

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

1.  A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease.

Authors:  M Losekoot; B Bakker; F Laccone; S Stenhouse; R Elles
Journal:  Eur J Hum Genet       Date:  1999 Feb-Mar       Impact factor: 4.246

2.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

Review 3.  Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease.

Authors:  J F Gusella; M E MacDonald
Journal:  Nat Rev Neurosci       Date:  2000-11       Impact factor: 34.870

4.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

Authors:  R R Brinkman; M M Mezei; J Theilmann; E Almqvist; M R Hayden
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

5.  ACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testing. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group.

Authors: 
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

6.  Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium.

Authors:  P S Harper; C Lim; D Craufurd
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

7.  Family and molecular data for a fine analysis of age at onset in Huntington disease.

Authors:  F Squitieri; G Sabbadini; P Mandich; C Gellera; E Di Maria; E Bellone; B Castellotti; E Nargi; U de Grazia; M Frontali; A Novelletto
Journal:  Am J Med Genet       Date:  2000-12-11

8.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.

Authors:  J P Warner; L H Barron; D J Brock
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

9.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  Reduced penetrance of the Huntington's disease mutation.

Authors:  S M McNeil; A Novelletto; J Srinidhi; G Barnes; I Kornbluth; M R Altherr; J J Wasmuth; J F Gusella; M E MacDonald; R H Myers
Journal:  Hum Mol Genet       Date:  1997-05       Impact factor: 6.150

View more
  22 in total

Review 1.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

2.  Discrepancies in reporting the CAG repeat lengths for Huntington's disease.

Authors:  Oliver W Quarrell; Olivia Handley; Kirsty O'Donovan; Christine Dumoulin; Maria Ramos-Arroyo; Ida Biunno; Peter Bauer; Margaret Kline; G Bernhard Landwehrmeyer
Journal:  Eur J Hum Genet       Date:  2011-08-03       Impact factor: 4.246

3.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Authors:  Annie Killoran; Kevin M Biglan; Joseph Jankovic; Shirley Eberly; Elise Kayson; David Oakes; Anne B Young; Ira Shoulson
Journal:  Neurology       Date:  2013-04-26       Impact factor: 9.910

4.  Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD.

Authors:  Nancy R Downing; Spencer Lourens; Isabella De Soriano; Jeffrey D Long; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 5.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

6.  HD CAG-correlated gene expression changes support a simple dominant gain of function.

Authors:  Jessie C Jacobsen; Gillian C Gregory; Juliana M Woda; Morgan N Thompson; Kathryn R Coser; Vidya Murthy; Isaac S Kohane; James F Gusella; Ihn Sik Seong; Marcy E MacDonald; Toshi Shioda; Jong-Min Lee
Journal:  Hum Mol Genet       Date:  2011-05-02       Impact factor: 6.150

7.  Decreasing uptake of predictive testing for Huntington's disease in a German centre: 12 years' experience (1993-2004).

Authors:  Christiane Bernhardt; Anne-Marie Schwan; Peter Kraus; Joerg Thomas Epplen; Erdmute Kunstmann
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

Review 8.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 9.  Therapeutic approaches to preventing cell death in Huntington disease.

Authors:  Anna Kaplan; Brent R Stockwell
Journal:  Prog Neurobiol       Date:  2012-08-28       Impact factor: 11.685

10.  HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Authors:  Miriam Moscovitch-Lopatin; Rachel E Goodman; Shirley Eberly; James J Ritch; H Diana Rosas; Samantha Matson; Wayne Matson; David Oakes; Anne B Young; Ira Shoulson; Steven M Hersch
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.